Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi.

Overall 123 patients out of 211 with iPET were available for central review.

在211名接受iPET的患者中，共有123名患者的扫描结果可用于中心审查。

Of these, 43% were older than 60, 33% had high-risk FLIPI2, and 47% received rituximab-bendamustine as the induction regimen. iPET showed a complete metabolic response (CMR) in 83% of cases.

在这些患者中，43%的年龄超过60岁，33%具有高风险FLIPI2评分，47%接受了利妥昔单抗-苯达莫司汀作为诱导治疗方案。iPET显示83%的病例实现了完全代谢反应（CMR）。

CMR at the end-of-induction therapy PET scan (eoiPET) was confirmed in 91% of iPET-negative patients.

在诱导治疗结束时的PET扫描（eoiPET）中，91%的iPET阴性患者确认了完全代谢反应（CMR）。

The 5-year progression-free survival(PFS) was 70% for iPET-negative and 34% for iPET-positive cases.

在iPET阴性病例中，5年无进展生存（PFS）率为70%，而在iPET阳性病例中为34%。

In multivariate analysis, positive iPET was an independent prognostic factor for PFS.

在多变量分析中，iPET阳性是PFS的一个独立预后因素。

Combining iPET and eoiPET, the 3-year PFS was 78% for both negative iPET and eoiPET, with a reduced risk of progression compared to double-positive iPET/eoiPET cases.

结合iPET和eoiPET，对于iPET和eoiPET均为阴性的患者，3年无进展生存（PFS）率为78%，与iPET和eoiPET双阳性病例相比，进展风险降低。

The 5-year overall survivalrate was 96% for iPET-negative and 85% for DS 4-5.

对于iPET阴性患者，5年总生存（OS）率为96%，而对于DS 4-5的患者，5年总生存率为85%。

Our results confirm that iPET in patients with FL treated with standard ICT is a strong prognostic factor.

我们的研究结果证实，在接受标准ICT治疗的滤泡性淋巴瘤（FL）患者中，首次正电子发射断层扫描（iPET）是一个强有力的预后因素。

Assessment of early metabolic response in FL may be considered for defining a novel generation of early response-adapted trials in FL.

在滤泡性淋巴瘤（FL）患者中评估早期代谢反应，可以考虑用于定义FL新一代早期反应适应性试验。

This trial was registered at www.ClinicalTrials.gov as #NCT02063685.

该试验已在www.ClinicalTrials.gov上注册，注册号为#NCT02063685。